Condition: Glioblastoma Multiforme · Sponsor: VBI Vaccines Inc.
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of California, Irvine | Irvine, California, United States | — |
| University of California, San Diego | La Jolla, California, United States | — |
| University of California, Los Angeles Neuro-Oncology Program | Los Angeles, California, United States | — |
| Stanford | Stanford, California, United States | — |
| Miami Cancer Institute | Miami, Florida, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| The Valley Hospital - Neurosurgeons of New Jersey | Ridgewood, New Jersey, United States | — |
| The Neurological Institute of New York Columbia University Medical Center | New York, New York, United States | — |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| Providence - Swedish Medical Center | Seattle, Washington, United States | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03382977